Continuous Mesna Infusion Dosing with Ifosfamide
For continuous-infusion ifosfamide, administer mesna as a 20% bolus dose of the total ifosfamide dose, followed by a continuous infusion of mesna equal to 40% of the ifosfamide dose, continuing for 12 to 24 hours after completion of the ifosfamide infusion 1.
Dosing Algorithm
Initial Bolus
- Give mesna as an IV bolus equal to 20% of the total ifosfamide dose at the start of ifosfamide infusion
Continuous Infusion Component
- Follow with mesna continuous infusion at 40% of the ifosfamide dose
- Continue the mesna infusion for 12 to 24 hours beyond the completion of ifosfamide infusion
Total Mesna Dose
- The combined bolus (20%) plus continuous infusion (40%) equals 60% of the total ifosfamide dose
Clinical Reasoning
This recommendation comes directly from ASCO clinical practice guidelines 1 and represents the standard approach for continuous-infusion ifosfamide. The FDA labeling 2 primarily addresses fractionated bolus dosing schedules rather than continuous infusion protocols, making the ASCO guidelines the authoritative source for this specific scenario.
The rationale for extending mesna beyond ifosfamide completion (12-24 hours) relates to the continued formation of toxic metabolites even after ifosfamide infusion ends. This extended coverage is critical for preventing hemorrhagic cystitis, which directly impacts patient morbidity and quality of life.
Important Caveats
Very High-Dose Ifosfamide
For ifosfamide doses exceeding standard ranges, the optimal mesna dosing has not been established 1. Given the longer half-life of ifosfamide at very high doses, more frequent and prolonged mesna regimens may be necessary for maximum urotoxic protection. In these cases, consider extending the mesna infusion duration beyond 24 hours post-ifosfamide.
Practical Implementation
Research studies have successfully used 1:1 concentration ratios of ifosfamide to mesna for continuous infusion over multiple days 3, and some protocols have used mesna at 50% of the ifosfamide dose as continuous infusion 4. However, the guideline-recommended 60% total dose (20% bolus + 40% infusion) remains the standard of care.
Monitoring Requirements
- Maintain adequate hydration throughout treatment
- Monitor urine for hematuria
- If severe hematuria develops despite appropriate mesna dosing, consider dose reduction or discontinuation of ifosfamide 2
Compatibility Considerations
When mixing ifosfamide and mesna in the same infusion bag, ensure the final ifosfamide concentration does not exceed 50 mg/mL, as higher concentrations may reduce ifosfamide stability due to benzyl alcohol in mesna formulations 2.